LTR Pharma has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 December 2024.
Key highlights from this period include:
- Breakthrough Final Clinical Data: SPONTAN® achieves 470% faster absorption than oral PDE5 tablets showing it can be effective within 10 minutes
- Strategic Partnerships:
-
- Joint Venture with Restorative Sexual Health Clinic for an innovative online healthcare platform
- Agreement with Men’s Health Downunder to provide access to SPONTAN, Australia’s largest men’s health primary pharmacy network
- Early Platform Launch: Online telehealth platform went live ahead of Q1 2025 target
- Pharmacy Distribution Agreement: Secured post-quarter with Symbion, one of Australia’s largest pharmaceutical wholesalers serving over 3,900 pharmacy customers